Flow Forward Medical Inc., an Olathe, Kan.-based early-stage company focused on improving outcomes for hemodialysis patients through the creation of vascular access sites, closed $1.3m Series A financing.
The round was led by existing investor the Kansas Bioscience Authority (KBA).
The company, which had previously raised $4.4m in Series A funding, intends to use the the funds to continue the development of its Arteriovenous Fistula Eligibility (AFE) System™.
Led by F. Nicholas Franano, MD, President and CEO, Flow Forward develops the Arteriovenous Fistula Eligibility (AFE) System™, a small, minimally invasive blood pump system designed for temporary use to rapidly dilate peripheral veins through flow-mediated vascular remodeling prior to arteriovenous fistula (AVF) surgery.
In addition, Flow Forward also announced that it will receive a $225,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to test peripheral vein dilation with the AFE System prior to AVF creation in a nonclinical model and the appointment of Kurt Dasse, PhD, currently President and CEO of GeNO LLC, a biopharmaceutical company developing delivery systems for inhaled nitric oxide, a pharmacologic blood vessel dilator, to its board of directors.